Delving into the Latest Updates on Mavacamten with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MAVA, MAVA-Myokardia, HCM 1

+ [6]

Target

Cardiac myosin

Mechanism

Cardiac myosin inhibitors

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertrophic obstructive cardiomyopathyHypertrophic Cardiomyopathy without ObstructionHeart failure with normal ejection fraction+ [1]

Inactive Indication-

Originator Organization

Bristol Myers Squibb Co.

Active Organization

BMS Korea Co. Ltd.

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIG

+ [4]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (28 Apr 2022),

Hypertrophic obstructive cardiomyopathy

RegulationPriority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR), Breakthrough Therapy (US), Orphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC15H19N3O2

InChIKeyRLCLASQCAPXVLM-NSHDSACASA-N

CAS Registry1642288-47-8

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.

Start Date24 Jul 2024

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT06338202 / RecruitingNot Applicable

Real-World Effectiveness of MAVacamtEN in Canada (MAVEN): A Retrospective Physician Survey of Patient Charts

The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.

Start Date26 Jun 2024

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT06551129 / RecruitingNot Applicable

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Start Date10 May 2024

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Mavacamten

Login to view more data

100 Translational Medicine associated with Mavacamten

Login to view more data

100 Patents (Medical) associated with Mavacamten

Login to view more data

268

Literatures (Medical) associated with Mavacamten

01 Feb 2025·AMERICAN JOURNAL OF CARDIOLOGY

A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers

Article

Author: Gaballa, Andrew ; Dhingra, Lovedeep S ; Sen, Sounok ; Mehra, Nandini ; Bryde, Robyn ; Krumholz, Harlan M ; Desai, Milind Y ; Ali, Adel H ; Krumholz, Harlan M. ; Sangha, Veer ; Oikonomou, Evangelos K ; Martinez, Matthew W ; Aminorroaya, Arya ; Kramer, Christopher M ; Khera, Rohan

Artificial intelligence-enhanced electrocardiography (AI-ECG) can identify hypertrophic cardiomyopathy (HCM) on 12-lead ECGs and offers a novel way to monitor treatment response. Although the surgical or percutaneous reduction of the interventricular septum (SRT) represented initial HCM therapies, mavacamten offers an oral alternative. We aimed to assess the use of AI-ECG as a strategy to evaluate biologic responses to SRT and mavacamten. We applied an AI-ECG model for HCM detection to electrocardiography images from patients who underwent SRT across 3 sites: Yale New Haven Health System (YNHHS), Cleveland Clinic Foundation (CCF), and Atlantic Health System (AHS) and to electrocardiography images from patients receiving mavacamten at YNHHS. A total of 70 patients underwent SRT at YNHHS, 100 at CCF, and 145 at AHS. At YNHHS, there was no significant change in the AI-ECG HCM score before versus after SRT (before SRT: median 0.55 [interquartile range 0.24 to 0.77] vs after SRT: 0.59 [0.40 to 0.75]). The AI-ECG HCM scores also did not improve after SRT at CCF (0.61 [0.32 to 0.79] vs 0.69 [0.52 to 0.79]) and AHS (0.52 [0.35 to 0.69] vs 0.61 [0.49 to 0.70]). Of the 36 YNHHS patients on mavacamten therapy, the median AI-ECG score before starting mavacamten was 0.41 (0.22 to 0.77), which decreased significantly to 0.28 (0.11 to 0.50, p <0.001 by Wilcoxon signed-rank test) at the end of a median follow-up period of 237 days. In conclusion, we observed a lack of improvement in AI-based HCM score with SRT, in contrast to a significant decrease with mavacamten. Our approach suggests the potential role of AI-ECG for serial point-of-care monitoring of pathophysiologic improvement after medical therapy in HCM using ECG images.

16 Dec 2024·EUROPEAN HEART JOURNAL

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy

Article

Author: Hegde, Sheila M ; Lakdawala, Neal K ; Oręziak, Artur ; Jensen, Morten K ; Wheeler, Matthew T ; Shah, Ashish ; Seidler, Tim ; Fox, Shawna ; Garcia-Pavia, Pablo ; Barriales-Villa, Roberto ; Abraham, Theodore P ; Wojakowski, Wojciech ; Masri, Ahmad ; Choudhury, Lubna ; Wang, Andrew ; Balaratnam, Ganesh ; Owens, Anjali T ; Hagege, Albert ; Olivotto, Iacopo

Abstract:

Background and Aims:

Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects of mavacamten.

Methods:

Participants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion.

Results:

At the latest data cut-off, 211 (91.3%) of the 231 patients originally enrolled in MAVA-LTE still received mavacamten. Median (range) time on study was 166.1 (6.0–228.1) weeks; 185 (80.1%) and 99 (42.9%) patients had completed the Week 156 and 180 visits, respectively. Sustained reductions from baseline to Week 180 occurred in left ventricular outflow tract gradients [mean (standard deviation): resting, −40.3 (32.7) mmHg; Valsalva, −55.3 (33.7) mmHg], N-terminal pro B-type natriuretic peptide [median (interquartile range): −562 (−1162.5, −209) ng/L], and EQ-5D-5L score [mean (standard deviation): 0.09 (0.17)]. Mean left ventricular ejection fraction (LVEF) decreased from 73.9% (baseline) to 66.6% (Week 24) and 63.9% (Week 180). At Week 180, 74 (77.9%) of the 95 patients improved by at least one New York Heart Association class from baseline. Over 739 patient-years exposure, 20 patients (8.7%; exposure-adjusted incidence: 2.77/100 patient-years) experienced 22 transient reductions in LVEF to <50% resulting in temporary treatment interruption (all recovered LVEF of ≥50%). Five (2.2%) patients died (all considered unrelated to mavacamten).

Conclusions:

Long-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.

01 Dec 2024·JOURNAL OF CARDIAC FAILURE

Association between age or duration of diagnosis in obstructive hypertrophic cardiomyopathy and response to mavacamten treatment: Exploratory analysis of the EXPLORER-HCM trial

Article

Author: Wojdyla, Daniel M ; Nilles, Ester Kim ; Lakdawala, Neal K ; Sehnert, Amy ; Owens, Anjali Tiku ; Bach, Richard G ; Wang, Andrew ; Abraham, Theodore P ; Cresci, Sharon ; Saberi, Sara

BACKGROUND AND AIMS:

In patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM), it is unclear if response to cardiac myosin inhibition varies with older age or a longer duration of diagnosis. This study evaluated the response of these subgroups to mavacamten therapy for all primary, secondary, and exploratory endpoints in the EXPLORER-HCM trial (ClinicalTrials.gov: NCT03470545).

METHODS:

Patients were stratified by age (≤60 vs. >60 years) and duration of HCM diagnosis (≤5 vs. >5 years). To estimate treatment differences and evaluate age and diagnosis duration by treatment interaction, analysis of covariance was used to model changes in continuous endpoints and a generalized linear model was used for binary endpoints.

RESULTS:

Older patients were more frequently female (53% vs. 29%), with a lower prevalence of pathogenic/likely pathogenic HCM gene variants (17% vs. 36%), lower mean peak oxygen consumption (pVO₂) (17.6 vs. 21.1 ml/kg/min), and a higher mean NT-proBNP level (817 vs. 592 ng/L) but similar NYHA classes and quality of life scores. Patients with a longer vs. shorter diagnosis duration had similar mean ages (59.0±11.6 vs. 57.9±12.3 years) but more family history of HCM (38% vs. 16%) and a higher mean NT-pro BNP level (938±118 vs. 494±145 ng/ml). No differences were observed in improvement in peak oxygen consumption, NYHA class, or patient-reported outcomes among older patients and those with a longer duration of diagnosis.

CONCLUSIONS:

In EXPLORER-HCM, mavacamten treatment had a similar benefit for all primary, secondary, and exploratory endpoints in patients with symptomatic, obstructive HCM regardless of age or duration of diagnosis.

135

News (Medical) associated with Mavacamten

02 Dec 2024

·endpts.com

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Plus, news about Cytokinetics, Theratechnologies, KisoJi Biotechnology and XOMA Royalty: Senti Bio touts early Phase 1 CAR-NK data, stock soars: Two of three patients who received the low dose of Senti’s treatment achieved a complete response as of the Sept. 19 data cutoff. Senti expects to enroll 20 patients in the study. Its stock rose more than 150% in premarket trading on Monday, and the company also said it secured a $37.6 million PIPE. — Max Gelman China startup nabs $42M Series A: Allink Biotherapeutics, which was founded in 2023, is focused on bispecifics and antibody-drug conjugates. The money will help fund two pipeline programs called ALK201 and ALK202 through Phase 1 trials, as well as push forward other efforts in oncology and immunology. The round was led by Lanchi Ventures. — Max Gelman Cytokinetics’ heart drug gets FDA decision date: The biotech announced that the FDA has set a deadline of Sept. 26 to decide whether to approve aficamten for a heart condition called obstructive hypertrophic cardiomyopathy. The agency currently has no plans to hold an advisory committee. If approved, the treatment would compete with Bristol Myers Squibb’s Camzyos, which is currently the only cardiac myosin inhibitor approved in the US. — Lei Lei Wu Theratechnologies reveals financing: The Montreal biotech said it could get up to $75 million from TD Bank and Investissement Québec via credit facilities. Some of the loans will go toward paying off existing credit facilities and bankroll business development. The company had about $20 million in cash at the end of November. — Kyle LaHucik KisoJi gets $41M to advance TROP2 program: The company plans to use the money to get KJ-103, its lead compound, into Phase 1 testing for solid tumors. Funds include “the conversion of previously funded convertible debentures.” Investissement Québec and Lumira Ventures led the financing. — Max Gelman XOMA’s latest royalty deal: The royalty company bought Pulmokine for $20 million in cash. The move gives XOMA access to a milestone and royalty stream from Pulmokine’s interest in seralutinib, the pulmonary arterial hypertension drug it licensed to Gossamer Bio. The drug is now in Phase 3, with a readout slated for late 2025. — Kyle LaHucik

Phase 1Phase 3Drug ApprovalADC

02 Dec 2024

·www.biopharmadive.com

Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date

Today, a brief rundown of news involving Novocure and Merus, as well as updates from Cytokinetics, Fate Therapeutics and Bluebird bio that you may have missed.Novocure said its electrical field-emitting device alongside chemotherapy helped people with locally advanced pancreatic cancer live longer than those who received only chemo in a Phase 3 trial. Trial participants treated with Novocures therapy survived for an average of just over 16 months, a statistically significant, two-month difference versus chemo alone, the company said. Novocure intends to file for regulatory approval in pancreatic cancer. The device is already cleared to treat glioblastoma, mesothelioma and non-small cell lung cancer. Jonathan GardnerMerus has licensed to Partner Therapeutics U.S. rights to its experimental cancer drug zenocutuzumab for an undisclosed sum, the companies announced Monday. An antibody drug, zenocutuzumab is under Food and Drug Administration review for use treating NRG1 fusion-positive tumors. The agency recently extended its evaluation and now expects to reach a decision on approval by Feb. 4, 2025. Ned PagliaruloThe Food and Drug Administration will decide by Sept. 26, 2025, whether to approve Cytokinetics heart drug aficamten in obstructive hypertrophic cardiomyopathy, the company said Monday. The agency accepted Cytokinetics application, which was based on the results of a Phase 3 trial showing use of aficamten improved exercise capacity for people with the condition. If approved, aficamten will compete with Bristol Myers Squibbs Camzyos, approved in 2022. The announcement follows moves by Cytokinetics to sell partial rights to the drug, including a royalty deal with Royalty Pharma and a Japanese licensing deal with Bayer. Cytokinetics previously had another heart failure drug rejected by the FDA. Jonathan GardnerThe FDA is now formally investigating cases of blood cancer following treatment with Bluebird bios gene therapy Skysona. The Nov. 27 notice from the agency cites cases Bluebird previously reported, details of which were published in October in The New England Journal of Medicine. No new cases or safety information preceded the FDAs announcement, a Bluebird spokesperson confirmed to BioPharma Dive. However, the agency did recommend that providers carefully consider alternative therapies like a hematopoietic stem cell transplant for prospective patients who have a matched donor, due to the blood cancer risk. Ned PagliaruloFate Therapeutics president and CEO Scott Wolchko will retire at the end of the year, ending a nearly decade-long stint running the natural killer cell therapy developer. The company said on Nov. 29 that longtime research chief Bob Valamehr will take over as its head at the start of 2025, with Wolchko transitioning to a strategic adviser. Fate previously only developed cancer therapies. But the company reset in 2023 and, like many of its peers, has made autoimmune disease research a focus as well. One program is now in early-stage testing in lupus. Ben Fidler '

Phase 3Clinical ResultGene TherapyCell Therapy

20 Nov 2024

·www.prnewswire.com

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

MONTREAL, Nov. 20, 2024 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce the appointment of Amy Sehnert, MD, as Chief Medical Officer (CMO). Dr. Sehnert will lead the clinical development and strategy for Thryv Therapeutics' expanding cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1) – a kinase implicated in adverse electrical and structural remodeling of the heart. Dr. Sehnert is a pediatric cardiologist with 20 years of experience as a serial and founding medical lead at innovative biotech companies introducing precision diagnostics and therapeutics to the clinic. Dr. Sehnert joins Thryv Therapeutics from Bristol Myers Squibb (BMS), where she held leadership roles of increasing responsibility and most recently served as Vice President and Global Program Lead for cardiovascular assets transitioning from early to late development. Prior to her time at BMS, Dr. Sehnert served as Vice President, Clinical Science at MyoKardia, Inc., where she played a pivotal role in the development and approval of Camzyos® - a groundbreaking treatment for hypertrophic cardiomyopathy (HCM) - contributing to the $14 billion acquisition of MyoKardia by BMS in 2020. "I am thrilled to join Thryv Therapeutics at such an important time in the company's journey," said Dr. Sehnert. "Thryv Therapeutics' cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide." Dr. Sehnert has also made notable contributions in other fields of medicine, such as maternal-fetal health, oncology, and genomics, leading early efforts in non-invasive prenatal testing (NIPT) and cell-free DNA applications now in wide clinical use. She holds a Doctor of Medicine degree from the University of Minnesota, completed Pediatrics Residency at University of Colorado, and Fellowship in Pediatric Cardiology at UCSF followed by faculty appointments at UCSF and Stanford University. In 2022 she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and has been involved in numerous international collaborations, making her an internationally recognized expert in her field. "On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team," said Paul F. Truex, CEO of Thryv Therapeutics. "Dr. Sehnert brings a wealth of medical and clinical development knowledge in the field of cardiometabolic and genetic diseases. Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases and leadership qualities will be invaluable as we enter the next phase of clinical development of our SGK1 portfolio." Dr. Philip Sager, Thryv Therapeutics' founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company's portfolio advances into later stage clinical studies. "Philip and his collaborators originally developed unique insights into the clinical potential for SGK1 in various cardiometabolic diseases and in particular, Long QT Syndrome. His tireless leadership and relentless passion for exploring these initial ideas advanced Thryv Therapeutics' portfolio to its current stage," said Paul F. Truex. "We're thankful for his continued, on-going contributions in his new role to all of our clinical programs and we are inspired by his commitment to finding treatments for these patient communities." About Thryv Therapeutics Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective serum glucocorticoid inducible kinase 1 (SGK1) inhibitors to treat heart failure, atrial fibrillation, Long QT Syndrome and other cardiometabolic and cardiorenal diseases. Numerous animal models have demonstrated that activation of SGK1 leads to inappropriate electrical and structural remodeling of the heart contributing to adverse outcomes in heart failure, atrial fibrillation, and genetic channelopathies, such as Long QT Syndrome. For more information, please visit . SOURCE Thryv Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeAcquisition

100 Deals associated with Mavacamten

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14921

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertrophic obstructive cardiomyopathy	US	Bristol Myers Squibb Co.	28 Apr 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	US	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	CN	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	JP	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	AU	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	AT	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	BE	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	BR	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	CA	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	CZ	Bristol Myers Squibb Co.	14 Dec 2022
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	DK	Bristol Myers Squibb Co.	14 Dec 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05174416 (CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	81	Mavacamten (Mavacamten)	rdpcvuuwgq(ferrqjsyxs) = helhhtnoxt tchikslmtc (duihnkecmc, xeptcfviom - uiaxrivmzh) View more	-	19 Sep 2024
				Placebo (Placebo)	rdpcvuuwgq(ferrqjsyxs) = jvnmydrlvo tchikslmtc (duihnkecmc, shxcoumpde - xtpnjjerby) View more
NCT03723655 (EXPLORER-LTE, BusinessWire) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy	251	CAMZYOS® (mavacamten)	juieyqddct(lcxiearsjw) = mobqniscjs xeqnmtxdom (xgvbtryiwc ) View more	Positive	01 Sep 2024
ESC2024	Not Applicable	Hypertrophic obstructive cardiomyopathy	-	Mavacamten 2.5 mg	dinbajxggz(owfmnxotju) = jtvikazutq ajiqcldyzp (bmlzznkdkz ) View more	-	31 Aug 2024
				Mavacamten 5 mg	dinbajxggz(owfmnxotju) = jhebcfevmr ajiqcldyzp (bmlzznkdkz ) View more
NCT05135871 (CTgov)	Phase 1	Cardiomyopathy, Hypertrophic	45	Mavacamten (Cohort 1: Mavacamten 15 mg)	rdcqrehbsr(mzylpwkwcq) = dciffsbauf akshgpujhh (aoncxfoqvn, dvpfwyywfa - bmsfcjrioz) View more	-	25 Jul 2024
				Mavacamten (Cohort 2: Mavacamten 25 mg)	rdcqrehbsr(mzylpwkwcq) = hbhsrblpjd akshgpujhh (aoncxfoqvn, qsvpgiefsz - yxppvbclxr) View more
NCT03496168 (PIONEER-OLE, Pubmed \| J Am Heart Assoc) Manual	Phase 2	Hypertrophic obstructive cardiomyopathy NT-proBNP	12	Mavacamten 5 mg	izfmtxnksp(nhvsnzgrtr) = Treatment-emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. swcfqekmfw (slzhmrefgs ) View more	Positive	09 Apr 2024
NCT03470545 (EXPLORER-HCM, Pubmed \| Circulation) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy plasma NT-proBNP	-	Mavacamten	pakclghiia(icsplkdosa) = vnnezrgdwb vwnnottbts (qhzbyivcwu ) View more	Similar	13 Feb 2024
				mavacamten	pakclghiia(icsplkdosa) = ixmyklclsy vwnnottbts (qhzbyivcwu ) View more
NCT04349072 (VALOR-HCM, Pubmed \| JAMA Cardiol)	Phase 3	Cardiomyopathy, Hypertrophic	112	Mavacamten	tsvvzjlumv(xcqhvlaimi) = vlnmbhfmnb adngpszcjg (wxtpmumnfc ) View more	Positive	01 Oct 2023
				Placebo	tsvvzjlumv(xcqhvlaimi) = ilfvtruciw adngpszcjg (wxtpmumnfc ) View more
NCT05174416 \| CTR20212890 (EXPLORER-CN, Biospace) Manual	Phase 3	Cardiomyopathy, Hypertrophic	81	Mavacamten	hgziqfjuvb(qkmszptcxe) = reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 82% greater for mavacamten compared with placebo apmstbiwrh (xzmsqsdgyp ) View more	Positive	28 Aug 2023
				placebo
EXPLORER-HCM (EMA) Manual	Phase 3	Hypertrophic Cardiomyopathy without Obstruction	251	Mavacamten	cdilghmfsv(pjnrwrhvxt) = dihxczejpw risrbzsizk (wnfpgebvui ) View more	Positive	24 Jul 2023
				Placebo	cdilghmfsv(pjnrwrhvxt) = yulbxqkngm risrbzsizk (wnfpgebvui ) View more
NCT04349072 (VALOR-HCM, CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	112	Mavacamten (Mavacamten)	tzhtzxwdbn(erteujlgdz) = ifyyztcynd ynuuivlfpi (qryherhbqo, pjjvjcrivg - fimycogflu) View more	-	07 Mar 2023
				Placebo+Mavacamten (Placebo to Mavacamten)	tzhtzxwdbn(erteujlgdz) = wmssrnflwi ynuuivlfpi (qryherhbqo, loerwtvmnq - vxmxcadgqp) View more